DOI : https://doi.org/10.18517/ijaseit.14.6.20019

Transcriptomic Analysis of Coagulation Gene Expression in COVID-19 Patients

Ika Kurnia Febrianti (1), Andani Eka Putra (2), Raveinal (3), Aisyah Elliyanti (4)
(1) Doctoral Programme of Biomedical, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
(2) Department of Microbiology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
(3) Department of Internal Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
(4) Nuclear Medicine Division, Department of Radiology, Faculty of Medicine, Universitas Andalas, Padang, Indonesia
Fulltext View | Download
How to cite (IJASEIT) :
Febrianti, Ika Kurnia, et al. “Transcriptomic Analysis of Coagulation Gene Expression in COVID-19 Patients”. International Journal on Advanced Science, Engineering and Information Technology, vol. 14, no. 6, Dec. 2024, pp. 2045-52, doi:10.18517/ijaseit.14.6.20019.
Citation Format :
The immunopathogenesis of COVID-19 infection is reported to begin with the entry of the SARS-CoV-2 virus into the human body through droplets, entering the lungs, and binding to the ACE-2 receptor. Meanwhile, activated macrophages stimulate an immune and inflammatory response, activating the coagulation cascade. This activation in COVID-19 patients can exacerbate the condition and may result in acute respiratory distress syndrome (ARDS). The coagulation cascade is influenced by the expression of related genes, including F3, F5, F8, F12, F13A1, VWF, THBD, PROC, PROCR, PROS1, SERPINE1, A2M, and PLAUR. This cross-sectional study was conducted in 2022, with 22 mild COVID-19 cases, 35 moderate-to-severe cases, and 20 healthy control individuals from Dr. M. Djamil Padang General Hospital in West Sumatra, Indonesia. Coagulation gene expression data using the RNA-Seq method with transcriptomic analysis were collected and recorded in transcript per-million (TPM) units. The results showed a significant difference in the expression of coagulation genes in moderate-to-severe compared to mild COVID-19 patients and healthy controls. The analysis of log2 folds change has a statistically significant increase observed in the expression of coagulation genes and a significant difference in the expression of coagulation genes among moderate-to-severe and mild patients, as well as healthy controls. The results underscored the impact of COVID-19 infection on the activity of coagulation cascade genes, which could influence the condition of patients and serve as a reference for therapy.

M. Marietta, W. Ageno, A. Artoni, E. De Candia, P. Gresele, M. Marchetti, R. Marcucci, and A. Tripodi, “COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET),” Blood Transfusion, vol. 18, no. 3, pp. 167-169, 2020, doi:10.2450/2020.0083-20.

D. Borg, J. Farrugia, and C. M. Azzopardi, “SARS-CoV-2 related ARDS and invasive fungal infections in intensive care patients,” Clinical Infection in Practice, vol. 13, pp. 100127, 2022, doi:10.1016/j.clinpr.2021.100127.

E. D. M. Balsa, T. B. Ruso, N. G. Medrano, M. M. Guijarro, A. M. Perez, and A. A. Lopez, “Effect of the duration of prone position in ARDS patients during the SARS-CoV-2 pandemic,” Medicina Intensiva (English Edition), vol. 47, no. 10, pp. 575-582, 2023, doi:10.1016/j.medine.2023.03.011.

D. Frame et al., Defibrotide Therapy for SARS-CoV-2 ARDS,” CHEST Critical Care, vol. 162, no. 2, pp. 346-355, 2022, doi:10.1016/j.chest.2022.03.046.

E. Burn at al., “Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study,” The Lancet Infectious Diseases, vol. 22, no. 8, pp. 1142-1152, 2022, doi:10.1016/S1473-3099(22)00223-7.

K. W. Hendrickson, I. D. Peltan, and S. M. Brown, “The epidemiology of acute respiratory distress syndrome before and after Coronavirus Disease 2019,” Critical Care Clinics, vol. 37, no. 4, pp. 703-716, 2021, doi 10.1016/j.ccc.2021.05.001

G. D. Wool, and J. L. Miller, “The Impact of COVID-19 Disease on platelets and coagulation,” Pathobiology: Journal of Immunopathology, Molecular and Cellular Biology, vol. 88, no. 1, pp. 15-27, 2021, doi; 10.1159/000512007.

M. G. Lazzaroni, S. Piantoni, S. Masneri, E. Garrafa, G. Martini, A. Tincani, L. Andreoli, and F. Franceschini, “Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system,” Blood Reviews, vol. 46, pp. 100745, 2021, doi: 10.1016/j.blre.2020.100745.

Y. Fu, H. Xue, T. Wang, Y. Ding, Y. Cui, and H, Nie, “Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport,” Biomedicine & Pharmacotherapy, vol, 163, pp. 114863, 2023, doi: 10.1016/j.biopha.2023.114863.

R. Seitz, L. Gürtler, and W. Schramm, “Thromboinflammation in COVID-19: Can α2-macroglobulin help to control the fire?,” Journal of Thrombosis and Haemostasis, vol 19, no.2, pp. 351-354, 2021, doi:10.1016/j.blre.2020.100745.

C. B. Keragala, and L. Medcalf, “Plasminogen: an enigmatic zymogen,” Blood, vol. 137, no. 21, pp. 1881-2889, 2021, doi:10.1182/blood.2020008951.

S. E. Ward, J. M. O'Sullivan, and J. S. O'Donnell, “The relationship between ABO blood group, von Willebrand factor, and primary hemostasis,” Blood, vol. 136, no. 25, pp. 2864–2874, 2020, doi:10.1182/blood.2020005843.

J. P. Reilly et al., “ABO histo-blood group and the von Willebrand factor axis in severe COVID-19,” CHEST Critical Care, vol. 1, no. 3, pp. 100023, 2023, doi: 10.1016/j.chstcc.2023.100023.

C. Kitel et al., “PB0818 impact of ABO blood group genotype on VWF level in carriers of type 3 von Willebrand Disease from the French von Willebrand disease reference center,” Research and Practice in Thrombosis and Haemostasis, vol. 7, Supplement 2, pp. 101536, 2023, doi: 10.1016/j.rpth.2023.101536.

A. Bonaventura, A. Vecchié, L. Dagna, K. Martinod, D. L. Dixon, B. W. Van Tassell, F. Dentali, F. Montecucco, S. Massberg, M. Levi, and A. Abbate, “Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19,” Nature Reviews: Immunology, vol. 21, no. 5, pp. 319-329, 2021, doi: 10.1038/s41577-021-00536-9.

B. Sadler, P. A. Christopherson, G. Haller, R. R. Montgomery, and J. D. Paola, “von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene,” Blood, vol. 137, no. 23, pp. 3277-3283, 2021, doi: 10.1182/blood.2020009999.

T. Won, et al., “Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs,” EBioMedicine, vol. 75, pp. 103812, 2022, doi: 10.1016/j.ebiom.2022.103812.

R. Majumder and T. Nguyen, “Protein S: function, regulation, and clinical perspectives,” Current Opinion in Hematology, vol. 28, no.5, pp. 339-344, 2021, doi: 10.1097/MOH.0000000000000663.

TS. Srivastava et al., “Gene variants in pro-coagulant and anti-coagulant genes could be prognostic genetic markers of COVID-19 susceptibility,” Heliyon, vol. 8, no. 11, pp. e11536, 2022, doi:10.1016/j.heliyon.2022.e11536.

S. Subramaniam, H. Kothari, and M. Bosmann, “Tissue factor in COVID-19-associated coagulopathy,” Thrombosis Research, vol. 220, pp. 35-47, 2022, doi: 10.1016/j.thromres.2022.09.025.

X. Yang et al., “Comparative analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of immunocompromised populations,” mySustems, vol. 9, no. 6, 2024, doi: 10.1128/msystems.01385-23.

R. Jain et al., “Host transcriptomic profiling of COVID-19 patients with mild, moderate, and severe clinical outcomes,” Computational and Structural Biotechnology Journal, vo. 19, no. 2021, pp. 153-160, 2021, doi: 10.1016/j.csbj.2020.12.016.

B. K. Manne et al., “Platelet gene expression and function in patients with COVID-19,” Blood, vol. 136, no. 11, pp. 1317-1329, 2020, doi:10.1182/blood.2020007214.

L. G. Gardinassi et al., “Chapter 8 - Transcriptomic approaches in COVID-19: From infection to vaccines,” Omics Approaches and Technologies in COVID-19, pp. 125-144, 2023, doi: 10.1016/B978-0-323-91794-0.00003-2.

H. Shivram et al., Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19,” iScience, vol. 26, no. 9, 2023, doi:10.1016/j.isci.2023.107597.

S. Yegorov et al., “Epidemiology, clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide retrospective cohort study,” The Lancet Regional Health - Europe, vol 4. pp. 100096, 2021, doi: 10.1016/j.lanepe.2021.100096.

K. Kragholm et al., “Association between male sex and outcomes of coronavirus disease 2019 (COVID-19)-A Danish nation wide, register-based study,” Clinical. Infectious Diseases, vol. 73, pp. e4025–e4030, 2021, doi: 10.1093/cid/ciaa924.

Y. Shi, X. Yu, H. Zhao, H. Wang, R. Zhao, and J. Sheng, “Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan,” Critical Care, vol. 24, no. 21, pp. 32188484, 2020, doi: 10.1186/s13054-020-2833-7.

D. C. P. Justino, D. F. O. Silva, K. T. D. S. Costa, T. N. B. de Morais, and F. B. de Andrade, ”Prevalence of comorbidities in deceased patients with COVID-19: A systematic review,” Medicine (Baltimore), vol. 101, no. 38, pp. e30246. 2022, doi:10.1097/MD.0000000000030246.

H. Englert et al., “Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation,” EBioMedicine, vol 67, pp. 103382, 2021, doi:10.1016/j.ebiom.2021.103382.

I. Mancini et al., “The ADAMTS13-von Willebrand factor axis in COVID-19 patients,” Journal of Thrombosis and Haemostasis, vol. 19, no. 2, pp. 513-521, 2021, doi: 10.1111/jth.15191.

P. G. Asteris et al., “Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks,” Nature Reviews Molecular Cell Biology, vol. 26, no. 5, pp. 1445–1455, 2022, doi: 10.1111/jcmm.17098.

T. J. Girard et al., “Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease,” Journal of Thrombosis and Haemostasis, vol. 21, no. 3, pp. 629-638, 2022, doi:10.1016/j.jtha.2022.11.033.

A. Elshafie, E. Foda, M. M. Yousef, and K. A. A. El-Naby, “Evaluation of protein C and S levels in patients with COVID-19 infection and their relation to disease severity,” The Egyptian Journal of Internal Medicine., vol. 35, no. 1, pp. 36845330. 2023, doi:10.1186/s43162-023-00195-3.

A. E. Mast, A. S. Wolberg, D. Gailani, M. R. Garvin, C. Alvarez, J. I. Miller, B. Aronow, and D. Jacobson, “SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung,” eLife, vol. 10, pp. e64330, 2021, doi: 10.7554/eLife.64330.

J. A. Stefely, B. B. Christensen, T. Gogakos, J. K. C. Sullivan, G. G. Montgomery, J. P. Barranco, and E. M. Van Cott, “Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism,” American Journal of Hematology, vol. 95, no. 12, pp. 1522-1530, 2020, doi: 10.1002/ajh.25979.

K. A. Overmyer et al., “Large-scale multi-omic analysis of COVID-19 severity,” Cell System, vol. 12, no. 1, pp. 23-40, 2021, doi:10.1016/j.cels.2020.10.003.

F. C. Ceballos et al., “Are reduced levels of Ccagulation proteins upon admission linked to COVID-19 severity and mortality?,” Frontiers in Medicine, vol. 8, pp. 718053, 2021, doi: 10.3389/fmed.2021.718053.

N. Tang, D. Li, X. Wang, and Z. Sun, “Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia,” Journal of Thrombosis and Haemostasis, vol 18, no. 4, pp. 844-847, 2020, doi: 10.1111/jth.14768.

L. E. Stoichitoiu, L. Pinte, M. I. Balea, V. Nedelcu, C. Badea, and C. Baicus, “Anticoagulant protein S in COVID-19: low activity, and associated with outcome,” Romanian Journal of Internal Medicine, vol. 58, no. 4, pp. 251–258, 2020, doi: 10.2478/rjim-2020-0024.

B. Puthusseri, A. Marudamuthu, N. Tiwari, J. Fu, S. Idell, and S. Shetty, “Regulation of p53-mediated changes in the uPA-fibrinolytic system and in lung injury by loss of surfactant protein C expression in alveolar epithelial cells,” American Journal of Physiology, vol. 312, no. 6, pp. 783-796, 2017, doi: 10.1152/ajplung.00291.2016.

O. Deckmyn et al., “Clinical interest of serum Alpha-2 macroglobulin, Apolipoprotein A1, and Haptoglobin in patients with non-alcoholic fatty liver disease, with and without Type 2 Diabetes, before or during COVID-19,” EBioMedicines, vol. 10, no. 3, pp. 35327501, 2022, doi:10.3390/biomedicines10030699.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).